NEWS

News Articles

Evox Therapeutics Receives up to €800M from Takeda To Tackle Rare Diseases

March 27, 2020

The Japanese pharmaceutical company Takeda has struck a deal worth up to €803M with UK biotech Evox Therapeutics to develop rare disease treatments delivered to cells via nanocapsules called exosomes. As part of the deal, Evox will use its proprietary technology platform to modify and load RNA and protein drugs into exosomes and target the…

Read More

GEORGIA STATE SCIENTISTS ARE JOINING THE RACE TO UNRAVEL HOW THE NEW CORONAVIRUS OPERATES — AND FIND EFFECTIVE TREATMENTS.

March 27, 2020

Schools closed. Workers logging in remotely. Streets empty. Businesses shuttered. The coronavirus pandemic is upending daily life throughout the world, and one of the biggest unknowns is “for how long?” The answer to that question depends on a number of factors, including how quickly scientists can learn more about how the virus, known as SARS-CoV-2,…

Read More

FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

March 26, 2020

The recently FDA-approved GENOSYL® inhaled nitric oxide may have pulmonary and antiviral benefits in treating pulmonary hypertension and acute infectious diseases associated with the novel coronavirus1  GENOSYL® DS facilitates outpatient use of inhaled nitric oxide in the treatment of cardiopulmonary symptoms associated with COVID-19 Read original article here. March 26, 2020 – VERO Biotech LLC, an Atlanta,…

Read More

NIH, CDC to See Funding Boosts in Stimulus Bill

March 25, 2020

NIH is slated to receive an additional $945 million to combat Covid-19 under the Senate’s economic relief package, bringing the agency’s total influx of coronavirus money to nearly $1.8 billion. The Senate is aiming to vote Wednesday on the spending plan, after reaching a deal with the White House. It’s the third coronavirus response legislation, and…

Read More

GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update

March 25, 2020

Recent Pivot to COVID-19 Vaccine Development; Continued Advancements in Other Infectious Disease and Immuno-Oncology Programs ATLANTA, GA, March 25, 2020 – GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2019 and provided an update on its…

Read More

Industry Welcomes Government Direction On Allocation of Ventilators

March 24, 2020

Collaboration With FEMA Would Speed Delivery To Patients Where Needed Most WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today sent a letter to the Federal Emergency Management Agency (FEMA) and the administration calling for centralization of procurement and allocation decision-making for medical ventilators to address the coronavirus pandemic and help ensure appropriate access to health care providers…

Read More